Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription Articles published in Mol Psychiatry Retrieve available abstracts of 269 articles: HTML format

Single Articles

January 2025
1. CHESTNYKH D, Muhle C, Schumacher F, Kalinichenko LS, et al
   Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
   Mol Psychiatry. 2025 Jan 17. doi: 10.1038/s41380-025-02893.
   PubMed     Abstract available
   
   
   
2. MARQUES D, Vaziri N, Greenway SC, Bousman C, et al
   DNA methylation and histone modifications associated with antipsychotic treatment: a systematic review.
   Mol Psychiatry. 2025;30:296-309.
   PubMed     Abstract available
   
   
   
3. CIULKINYTE A, Mountford HS, Fontanillas P, Bates TC, et al
   Genetic neurodevelopmental clustering and dyslexia.
   Mol Psychiatry. 2025;30:140-150.
   PubMed     Abstract available
   
   
   
4. LI X, Xue C, Zhu Z, Yu X, et al
   Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis.
   Mol Psychiatry. 2025;30:111-121.
   PubMed     Abstract available
   
   
   December 2024
5. EISENBERG DP, Blackman RK, Tietcheu MG, Kohn PD, et al
   Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D(2/3) receptor availability in healthy individuals.
   Mol Psychiatry. 2024 Dec 27. doi: 10.1038/s41380-024-02873.
   PubMed     Abstract available
   
   
   
6. XIA C, Alliey-Rodriguez N, Tamminga CA, Keshavan MS, et al
   Genetic analysis of psychosis Biotypes: shared Ancestry-adjusted polygenic risk and unique genomic associations.
   Mol Psychiatry. 2024 Dec 21. doi: 10.1038/s41380-024-02876.
   PubMed     Abstract available
   
   
   
7. SOLMI M, Fornaro M, Caiolo S, Lussignoli M, et al
   Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.
   Mol Psychiatry. 2024 Dec 18. doi: 10.1038/s41380-024-02733.
   PubMed     Abstract available
   
   
   
8. COHEN LS, Arakelian M, Church TR, Dunk MM, et al
   The phenomenology of postpartum psychosis: preliminary findings from the Massachusetts General Hospital Postpartum Psychosis Project.
   Mol Psychiatry. 2024 Dec 6. doi: 10.1038/s41380-024-02856.
   PubMed     Abstract available
   
   
   
9. BERNSTEIN HG, Nussbaumer M, Vasilevska V, Dobrowolny H, et al
   Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration.
   Mol Psychiatry. 2024 Dec 5. doi: 10.1038/s41380-024-02861.
   PubMed     Abstract available
   
   
   
10. SCHALBROECK R, van Hooijdonk CFM, Bos DPA, Booij J, et al
    Chronic social stressors and striatal dopamine functioning in humans: A systematic review of SPECT and PET studies.
    Mol Psychiatry. 2024;29:3841-3856.
    PubMed     Abstract available
    
    
    November 2024
11. SABE M, Sulstarova A, Glangetas A, De Pieri M, et al
    Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
    Mol Psychiatry. 2024 Nov 27. doi: 10.1038/s41380-024-02800.
    PubMed     Abstract available
    
    
    
12. NELSON EA, Kraguljac NV, Bashir A, Cofield SS, et al
    A longitudinal study of hippocampal subfield volumes and hippocampal glutamate levels in antipsychotic-naive first episode psychosis patients.
    Mol Psychiatry. 2024 Nov 23. doi: 10.1038/s41380-024-02812.
    PubMed     Abstract available
    
    
    
13. WEIDENAUER A, Dajic I, Praschak-Rieder N, Willeit M, et al
    The dopaminergic basis of negative symptoms in schizophrenia: an addendum.
    Mol Psychiatry. 2024 Nov 20. doi: 10.1038/s41380-024-02828.
    PubMed    
    
    
    
14. CHEN L, Huai C, Song C, Wu S, et al
    Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.
    Mol Psychiatry. 2024 Nov 19. doi: 10.1038/s41380-024-02841.
    PubMed     Abstract available
    
    
    
15. NISHA AJI K, Lalang N, Ramos-Jimenez C, Rahimian R, et al
    Evidence of altered monoamine oxidase B, an astroglia marker, in early psychosis and high-risk state.
    Mol Psychiatry. 2024 Nov 7. doi: 10.1038/s41380-024-02816.
    PubMed     Abstract available
    
    
    
16. SOCRATES AJ, Mullins N, Gur RC, Gur RE, et al
    Polygenic risk of social isolation behavior and its influence on psychopathology and personality.
    Mol Psychiatry. 2024;29:3599-3606.
    PubMed     Abstract available
    
    
    
17. LUO J, Li L, Niu M, Kong D, et al
    Genetic regulation of human brain proteome reveals proteins implicated in psychiatric disorders.
    Mol Psychiatry. 2024;29:3330-3343.
    PubMed     Abstract available
    
    
    October 2024
18. LEE H, Lee JH, Lee S, Lim JS, et al
    Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses.
    Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02792.
    PubMed     Abstract available
    
    
    
19. DEVINE EA, Imami AS, Eby H, Sahay S, et al
    Neuronal alterations in AKT isotype expression in schizophrenia.
    Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02770.
    PubMed     Abstract available
    
    
    
20. SCOTT DS, Subramanian M, Yamamoto J, Tamminga CA, et al
    Schizophrenia pathology reverse-translated into mouse shows hippocampal hyperactivity, psychosis behaviors and hyper-synchronous events.
    Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02781.
    PubMed     Abstract available
    
    
    
21. DEMPSTER EL, Wong CCY, Burrage J, Hannon E, et al
    Methylomic signature of current cannabis use in two first-episode psychosis cohorts.
    Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02689.
    PubMed     Abstract available
    
    
    
22. KEANE BP, Abrham YT, Cole MW, Johnson BA, et al
    Functional dysconnectivity of visual and somatomotor networks yields a simple and robust biomarker for psychosis.
    Mol Psychiatry. 2024 Oct 4. doi: 10.1038/s41380-024-02767.
    PubMed     Abstract available
    
    
    
23. LIUFU C, Luo L, Pang T, Zheng H, et al
    Integration of multi-omics summary data reveals the role of N6-methyladenosine in neuropsychiatric disorders.
    Mol Psychiatry. 2024;29:3141-3150.
    PubMed     Abstract available
    
    
    September 2024
24. CHOE E, Kim M, Choi S, Oh H, et al
    MRI textural plasticity in limbic gray matter associated with clinical response to electroconvulsive therapy for psychosis.
    Mol Psychiatry. 2024 Sep 26. doi: 10.1038/s41380-024-02755.
    PubMed     Abstract available
    
    
    
25. SAPIENZA J, Martini F, Comai S, Cavallaro R, et al
    Psychedelics and schizophrenia: a double-edged sword.
    Mol Psychiatry. 2024 Sep 18. doi: 10.1038/s41380-024-02743.
    PubMed     Abstract available
    
    
    
26. KILTSCHEWSKIJ DJ, Reay WR, Cairns MJ
    Schizophrenia is associated with altered DNA methylation variance.
    Mol Psychiatry. 2024 Sep 13. doi: 10.1038/s41380-024-02749.
    PubMed     Abstract available
    
    
    
27. GARCIA-SAN-MARTIN N, Bethlehem RAI, Mihalik A, Seidlitz J, et al
    Molecular and micro-architectural mapping of gray matter alterations in psychosis.
    Mol Psychiatry. 2024 Sep 12. doi: 10.1038/s41380-024-02724.
    PubMed     Abstract available
    
    
    
28. NANI JV, Muotri AR, Hayashi MAF
    Peering into the mind: unraveling schizophrenia's secrets using models.
    Mol Psychiatry. 2024 Sep 8. doi: 10.1038/s41380-024-02728.
    PubMed     Abstract available
    
    
    
29. ROMANOVSKY E, Choudhary A, Peles D, Abu-Akel A, et al
    Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons.
    Mol Psychiatry. 2024 Sep 5. doi: 10.1038/s41380-024-02740.
    PubMed     Abstract available
    
    
    
30. PHADKE RA, Brack A, Fournier LA, Kruzich E, et al
    The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking.
    Mol Psychiatry. 2024 Sep 3. doi: 10.1038/s41380-024-02701.
    PubMed     Abstract available
    
    
    
31. CHAN JKN, Lee KCK, Correll CU, So YK, et al
    Adverse obstetric and neonatal outcomes associated with maternal schizophrenia-spectrum disorders and prenatal antipsychotic use: a meta-analysis of 37,214,330 pregnancy deliveries and propensity-score weighted population-based cohort study assessing
    Mol Psychiatry. 2024 Sep 2. doi: 10.1038/s41380-024-02723.
    PubMed     Abstract available
    
    
    
32. CROUSE JJ, Park SH, Byrne EM, Mitchell BL, et al
    Patterns of stressful life events and polygenic scores for five mental disorders and neuroticism among adults with depression.
    Mol Psychiatry. 2024;29:2765-2773.
    PubMed     Abstract available
    
    
    
33. GAITONDE SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, et al
    Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT(2A) receptor.
    Mol Psychiatry. 2024;29:2753-2764.
    PubMed     Abstract available
    
    
    
34. KAMPE A, Suvisaari J, Lahteenvuo M, Singh T, et al
    Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders.
    Mol Psychiatry. 2024;29:2733-2741.
    PubMed     Abstract available
    
    
    
35. GERACI F, Passiatore R, Penzel N, Laudani S, et al
    Sex dimorphism controls dysbindin-related cognitive dysfunctions in mice and humans with the contribution of COMT.
    Mol Psychiatry. 2024;29:2666-2677.
    PubMed     Abstract available
    
    
    August 2024
36. KAMBALI M, Li Y, Unichenko P, Feria Pliego JA, et al
    An increased copy number of glycine decarboxylase (GLDC) associated with psychosis reduces extracellular glycine and impairs NMDA receptor function.
    Mol Psychiatry. 2024 Aug 30. doi: 10.1038/s41380-024-02711.
    PubMed     Abstract available
    
    
    
37. AYMERICH C, Salazar de Pablo G, Pacho M, Perez-Rodriguez V, et al
    All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis.
    Mol Psychiatry. 2024 Aug 22. doi: 10.1038/s41380-024-02694.
    PubMed     Abstract available
    
    
    
38. LI Z, Mukherjee D, Duric B, Austin-Zimmerman I, et al
    Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents.
    Mol Psychiatry. 2024 Aug 2. doi: 10.1038/s41380-024-02668.
    PubMed     Abstract available
    
    
    
39. ALLOTT K, Chopra S, Rogers J, Dauvermann MR, et al
    Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action.
    Mol Psychiatry. 2024;29:2571-2574.
    PubMed    
    
    
    July 2024
40. FORNARO M, Caiazza C, Billeci M, Berk M, et al
    Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".
    Mol Psychiatry. 2024 Jul 18. doi: 10.1038/s41380-024-02645.
    PubMed     Abstract available
    
    
    
41. ARANDA S, Jimenez E, Canales-Rodriguez EJ, Verdolini N, et al
    Processing speed mediates the relationship between DDR1 and psychosocial functioning in euthymic patients with bipolar disorder presenting psychotic symptoms.
    Mol Psychiatry. 2024;29:2050-2058.
    PubMed     Abstract available
    
    
    June 2024
42. CAMPORESI S, Xin L, Golay P, Eap CB, et al
    Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study.
    Mol Psychiatry. 2024 Jun 7. doi: 10.1038/s41380-024-02631.
    PubMed     Abstract available
    
    
    
43. MARTINO M, Magioncalda P
    A working model of neural activity and phenomenal experience in psychosis.
    Mol Psychiatry. 2024 Jun 6. doi: 10.1038/s41380-024-02607.
    PubMed     Abstract available
    
    
    
44. CHO KIK, Zhang F, Penzel N, Seitz-Holland J, et al
    Excessive interstitial free-water in cortical gray matter preceding accelerated volume changes in individuals at clinical high risk for psychosis.
    Mol Psychiatry. 2024 Jun 3. doi: 10.1038/s41380-024-02597.
    PubMed     Abstract available
    
    
    
45. LIAO Y, Yu H, Zhang Y, Lu Z, et al
    Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.
    Mol Psychiatry. 2024;29:1857-1868.
    PubMed     Abstract available
    
    
    May 2024
46. STERN S, Zhang L, Wang M, Wright R, et al
    Monozygotic twins discordant for schizophrenia differ in maturation and synaptic transmission.
    Mol Psychiatry. 2024 May 4. doi: 10.1038/s41380-024-02561.
    PubMed     Abstract available
    
    
    
47. HILL MD, Gill SS, Le-Niculescu H, MacKie O, et al
    Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics.
    Mol Psychiatry. 2024;29:1528-1549.
    PubMed     Abstract available
    
    
    
48. YANG K, Hasegawa Y, Bhattarai JP, Hua J, et al
    Inflammation-related pathology in the olfactory epithelium: its impact on the olfactory system in psychotic disorders.
    Mol Psychiatry. 2024;29:1453-1464.
    PubMed     Abstract available
    
    
    April 2024
49. SPATHOPOULOU A, Sauerwein GA, Marteau V, Podlesnic M, et al
    Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia.
    Mol Psychiatry. 2024 Apr 29. doi: 10.1038/s41380-024-02568.
    PubMed     Abstract available
    
    
    
50. SHARKEY RJ, Bacon C, Peterson Z, Rootes-Murdy K, et al
    Differences in the neural correlates of schizophrenia with positive and negative formal thought disorder in patients with schizophrenia in the ENIGMA dataset.
    Mol Psychiatry. 2024 Apr 26. doi: 10.1038/s41380-024-02563.
    PubMed     Abstract available
    
    
    
51. SUPEKAR K, de Los Angeles C, Ryali S, Kushan L, et al
    Robust and replicable functional brain signatures of 22q11.2 deletion syndrome and associated psychosis: a deep neural network-based multi-cohort study.
    Mol Psychiatry. 2024 Apr 12. doi: 10.1038/s41380-024-02495.
    PubMed     Abstract available
    
    
    
52. TOTZEK JF, Chakravarty MM, Joober R, Malla A, et al
    Longitudinal inference of multiscale markers in psychosis: from hippocampal centrality to functional outcome.
    Mol Psychiatry. 2024 Apr 11. doi: 10.1038/s41380-024-02549.
    PubMed     Abstract available
    
    
    
53. OKADA N, Yahata N, Koshiyama D, Morita K, et al
    Longitudinal trajectories of anterior cingulate glutamate and subclinical psychotic experiences in early adolescence: the impact of bullying victimization.
    Mol Psychiatry. 2024;29:939-950.
    PubMed     Abstract available
    
    
    March 2024
54. CHEN S, Tan Y, Tian L
    Immunophenotypes in psychosis: is it a premature inflamm-aging disorder?
    Mol Psychiatry. 2024 Mar 26. doi: 10.1038/s41380-024-02539.
    PubMed     Abstract available
    
    
    
55. KOSKUVI M, Porsti E, Hewitt T, Rasanen N, et al
    Genetic contribution to microglial activation in schizophrenia.
    Mol Psychiatry. 2024 Mar 22. doi: 10.1038/s41380-024-02529.
    PubMed     Abstract available
    
    
    
56. TESFAYE M, Spindola LM, Stavrum AK, Shadrin A, et al
    Sex effects on DNA methylation affect discovery in epigenome-wide association study of schizophrenia.
    Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02513.
    PubMed     Abstract available
    
    
    
57. FEOLA B, Beermann A, Manzanarez Felix K, Coleman M, et al
    Data-driven, connectome-wide analysis identifies psychosis-specific brain correlates of fear and anxiety.
    Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02512.
    PubMed     Abstract available
    
    
    
58. BIGDELI TB, Barr PB, Rajeevan N, Graham DP, et al
    Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder.
    Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02472.
    PubMed     Abstract available
    
    
    
59. WARREN TL, Tubbs JD, Lesh TA, Corona MB, et al
    Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis.
    Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02457.
    PubMed     Abstract available
    
    
    February 2024
60. FOUNTOULAKIS KN, Tsapakis EM
    Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders.
    Mol Psychiatry. 2024 Feb 19. doi: 10.1038/s41380-024-02458.
    PubMed    
    
    
    
61. SONG J, Jonsson L, Lu Y, Bergen SE, et al
    Key subphenotypes of bipolar disorder are differentially associated with polygenic liabilities for bipolar disorder, schizophrenia, and major depressive disorder.
    Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02448.
    PubMed     Abstract available
    
    
    
62. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
    Correction: On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis.
    Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02481.
    PubMed    
    
    
    
63. KOTOV R, Carpenter WT, Cicero DC, Correll CU, et al
    Psychosis superspectrum II: neurobiology, treatment, and implications.
    Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02410.
    PubMed     Abstract available
    
    
    
64. ZHU Y, Maikusa N, Radua J, Samann PG, et al
    Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk.
    Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02426.
    PubMed     Abstract available
    
    
    
65. GEORGIADIS F, Lariviere S, Glahn D, Hong LE, et al
    Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study.
    Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02442.
    PubMed     Abstract available
    
    
    
66. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
    On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis.
    Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02415.
    PubMed     Abstract available
    
    
    
67. PODVIN S, Jones J, Kang A, Goodman R, et al
    Human iN neuronal model of schizophrenia displays dysregulation of chromogranin B and related neuropeptide transmitter signatures.
    Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02422.
    PubMed     Abstract available
    
    
    
68. SHAKESHAFT A, Martin J, Dennison CA, Riglin L, et al
    Estimating the impact of transmitted and non-transmitted psychiatric and neurodevelopmental polygenic scores on youth emotional problems.
    Mol Psychiatry. 2024;29:238-246.
    PubMed     Abstract available
    
    
    January 2024
69. CHUNG Y, Dienel SJ, Belch MJ, Fish KN, et al
    Altered Rbfox1-Vamp1 pathway and prefrontal cortical dysfunction in schizophrenia.
    Mol Psychiatry. 2024 Jan 25. doi: 10.1038/s41380-024-02417.
    PubMed     Abstract available
    
    
    
70. CHEN H, Lei Y, Li R, Xia X, et al
    Resting-state EEG dynamic functional connectivity distinguishes non-psychotic major depression, psychotic major depression and schizophrenia.
    Mol Psychiatry. 2024 Jan 24. doi: 10.1038/s41380-023-02395.
    PubMed     Abstract available
    
    
    
71. DAVIES C, Martins D, Dipasquale O, McCutcheon RA, et al
    Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.
    Mol Psychiatry. 2024 Jan 19. doi: 10.1038/s41380-024-02406.
    PubMed     Abstract available
    
    
    
72. WOLFF A, Northoff G
    Temporal imprecision of phase coherence in schizophrenia and psychosis-dynamic mechanisms and diagnostic marker.
    Mol Psychiatry. 2024 Jan 16. doi: 10.1038/s41380-023-02337.
    PubMed     Abstract available
    
    
    
73. JONAS KG, Cannon TD, Docherty AR, Dwyer D, et al
    Psychosis superspectrum I: Nosology, etiology, and lifespan development.
    Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02388.
    PubMed     Abstract available
    
    
    
74. SI S, Bi A, Yu Z, See C, et al
    Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study.
    Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02343.
    PubMed     Abstract available
    
    
    
75. RUBIO JM, Lencz T, Cao H, Kraguljac N, et al
    Replication of a neuroimaging biomarker for striatal dysfunction in psychosis.
    Mol Psychiatry. 2024 Jan 4. doi: 10.1038/s41380-023-02381.
    PubMed     Abstract available
    
    
    December 2023
76. DONG P, Voloudakis G, Fullard JF, Hoffman GE, et al
    Convergence of the dysregulated regulome in schizophrenia with polygenic risk and evolutionarily constrained enhancers.
    Mol Psychiatry. 2023 Dec 25. doi: 10.1038/s41380-023-02370.
    PubMed     Abstract available
    
    
    
77. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    The relationship between familial-genetic risk and pharmacological treatment in a Swedish national sample of patients with major depression, bipolar disorder, and schizophrenia.
    Mol Psychiatry. 2023 Dec 20. doi: 10.1038/s41380-023-02365.
    PubMed     Abstract available
    
    
    
78. KOMATSU H, Onoguchi G, Silverstein SM, Jerotic S, et al
    Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography.
    Mol Psychiatry. 2023 Dec 11. doi: 10.1038/s41380-023-02340.
    PubMed     Abstract available
    
    
    
79. OKADA N, Fukunaga M, Miura K, Nemoto K, et al
    Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification.
    Mol Psychiatry. 2023;28:5206-5216.
    PubMed     Abstract available
    
    
    
80. GRIECO SF, Johnston KG, Gao P, Garduno BM, et al
    Anatomical and molecular characterization of parvalbumin-cholecystokinin co-expressing inhibitory interneurons: implications for neuropsychiatric conditions.
    Mol Psychiatry. 2023;28:5293-5308.
    PubMed     Abstract available
    
    
    
81. WEI W, Deng L, Qiao C, Yin Y, et al
    Neural variability in three major psychiatric disorders.
    Mol Psychiatry. 2023;28:5217-5227.
    PubMed     Abstract available
    
    
    
82. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    Selecting cases of major psychiatric and substance use disorders in Swedish national registries on the basis of clinical features to maximize the strength or specificity of the genetic risk.
    Mol Psychiatry. 2023;28:5195-5205.
    PubMed     Abstract available
    
    
    
83. ZHENG H, Webster MJ, Weickert CS, Beasley CL, et al
    Cytomegalovirus antibodies are associated with mood disorders, suicide, markers of neuroinflammation, and microglia activation in postmortem brain samples.
    Mol Psychiatry. 2023;28:5282-5292.
    PubMed     Abstract available
    
    
    November 2023
84. NORTHOFF G, Daub J, Hirjak D
    Overcoming the translational crisis of contemporary psychiatry - converging phenomenological and spatiotemporal psychopathology.
    Mol Psychiatry. 2023;28:4492-4499.
    PubMed     Abstract available
    
    
    October 2023
85. OWEN MJ, Legge SE, Rees E, Walters JTR, et al
    Genomic findings in schizophrenia and their implications.
    Mol Psychiatry. 2023 Oct 18. doi: 10.1038/s41380-023-02293.
    PubMed     Abstract available
    
    
    
86. LESH TA, Iosif AM, Tanase C, Vlasova RM, et al
    Extracellular free water elevations are associated with brain volume and maternal cytokine response in a longitudinal nonhuman primate maternal immune activation model.
    Mol Psychiatry. 2023;28:4185-4194.
    PubMed     Abstract available
    
    
    
87. ARNATKEVICIUTE A, Lemire M, Morrison C, Mooney M, et al
    Trans-ancestry meta-analysis of genome wide association studies of inhibitory control.
    Mol Psychiatry. 2023;28:4175-4184.
    PubMed     Abstract available
    
    
    
88. RAVEN EP, Veraart J, Kievit RA, Genc S, et al
    In vivo evidence of microstructural hypo-connectivity of brain white matter in 22q11.2 deletion syndrome.
    Mol Psychiatry. 2023;28:4342-4352.
    PubMed     Abstract available
    
    
    September 2023
89. ODKHUU S, Kim WS, Tsogt U, Shen J, et al
    Network biomarkers in recovered psychosis patients who discontinued antipsychotics.
    Mol Psychiatry. 2023 Sep 29. doi: 10.1038/s41380-023-02279.
    PubMed     Abstract available
    
    
    
90. HARRISON PJ, Bannerman DM
    GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia.
    Mol Psychiatry. 2023 Sep 22. doi: 10.1038/s41380-023-02265.
    PubMed     Abstract available
    
    
    
91. ZHOU J, Xia Y, Li M, Chen Y, et al
    A higher dysregulation burden of brain DNA methylation in female patients implicated in the sex bias of Schizophrenia.
    Mol Psychiatry. 2023 Sep 11. doi: 10.1038/s41380-023-02243.
    PubMed     Abstract available
    
    
    
92. FLYNN LT, Gao WJ
    DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness.
    Mol Psychiatry. 2023 Sep 7. doi: 10.1038/s41380-023-02235.
    PubMed     Abstract available
    
    
    
93. SOLMI M, Cortese S, Vita G, De Prisco M, et al
    An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders.
    Mol Psychiatry. 2023;28:3671-3687.
    PubMed     Abstract available
    
    
    
94. MERRITT K, Luque Laguna P, Sethi A, Drakesmith M, et al
    The impact of cumulative obstetric complications and childhood trauma on brain volume in young people with psychotic experiences.
    Mol Psychiatry. 2023;28:3688-3697.
    PubMed     Abstract available
    
    
    
95. WOOTTON O, Shadrin AA, Mohn C, Susser E, et al
    Genome-wide association study in 404,302 individuals identifies 7 significant loci for reaction time variability.
    Mol Psychiatry. 2023;28:4011-4019.
    PubMed     Abstract available
    
    
    
96. CAMPBELL PD, Lee I, Thyme S, Granato M, et al
    Mitochondrial proteins encoded by the 22q11.2 neurodevelopmental locus regulate neural stem and progenitor cell proliferation.
    Mol Psychiatry. 2023;28:3769-3781.
    PubMed     Abstract available
    
    
    August 2023
97. BANAJ N, Vecchio D, Piras F, De Rossi P, et al
    Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses.
    Mol Psychiatry. 2023 Aug 29. doi: 10.1038/s41380-023-02221.
    PubMed     Abstract available
    
    
    
98. SALEH Y, Jarratt-Barnham I, Petitet P, Fernandez-Egea E, et al
    Negative symptoms and cognitive impairment are associated with distinct motivational deficits in treatment resistant schizophrenia.
    Mol Psychiatry. 2023 Aug 25. doi: 10.1038/s41380-023-02232.
    PubMed     Abstract available
    
    
    
99. LIU L, Qi X, Cheng S, Meng P, et al
    Epigenetic analysis suggests aberrant cerebellum brain aging in old-aged adults with autism spectrum disorder and schizophrenia.
    Mol Psychiatry. 2023 Aug 24. doi: 10.1038/s41380-023-02233.
    PubMed     Abstract available
    
    
    
100. PORTER A, Fei S, Damme KSF, Nusslock R, et al
     A meta-analysis and systematic review of single vs. multimodal neuroimaging techniques in the classification of psychosis.
     Mol Psychiatry. 2023 Aug 10. doi: 10.1038/s41380-023-02195.
     PubMed     Abstract available
     
     
     
101. NURMI EL, Laughlin CP, de Wit H, Palmer AA, et al
     Polygenic contributions to performance on the Balloon Analogue Risk Task.
     Mol Psychiatry. 2023;28:3524-3530.
     PubMed     Abstract available
     
     
     
102. HETTEMA JM, van den Oord EJCG, Zhao M, Xie LY, et al
     Methylome-wide association study of anxiety disorders.
     Mol Psychiatry. 2023;28:3484-3492.
     PubMed     Abstract available
     
     
     July 2023
103. MYRAN DT, Pugliese M, Roberts RL, Solmi M, et al
     Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis.
     Mol Psychiatry. 2023 Jul 27. doi: 10.1038/s41380-023-02185.
     PubMed     Abstract available
     
     
     
104. SOLMI M, Seitidis G, Mavridis D, Correll CU, et al
     Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019.
     Mol Psychiatry. 2023 Jul 27. doi: 10.1038/s41380-023-02138.
     PubMed     Abstract available
     
     
     
105. MOON SY, Park H, Lee W, Lee S, et al
     Magnetic resonance texture analysis reveals stagewise nonlinear alterations of the frontal gray matter in patients with early psychosis.
     Mol Psychiatry. 2023 Jul 27. doi: 10.1038/s41380-023-02163.
     PubMed     Abstract available
     
     
     
106. FOND G, Falissard B, Nuss P, Collin C, et al
     How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients.
     Mol Psychiatry. 2023 Jul 21. doi: 10.1038/s41380-023-02154.
     PubMed     Abstract available
     
     
     
107. BOYER L, Falissard B, Nuss P, Collin C, et al
     Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.
     Mol Psychiatry. 2023 Jul 21. doi: 10.1038/s41380-023-02175.
     PubMed     Abstract available
     
     
     June 2023
108. MAHADEVAN AS, Cornblath EJ, Lydon-Staley DM, Zhou D, et al
     Alprazolam modulates persistence energy during emotion processing in first-degree relatives of individuals with schizophrenia: a network control study.
     Mol Psychiatry. 2023 Jun 23. doi: 10.1038/s41380-023-02121.
     PubMed     Abstract available
     
     
     
109. SOLMI M, Soardo L, Kaur S, Azis M, et al
     Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment.
     Mol Psychiatry. 2023 Jun 9. doi: 10.1038/s41380-023-02029.
     PubMed     Abstract available
     
     
     May 2023
110. YU Y, Fu Y, Yu Y, Tang M, et al
     Investigating the shared genetic architecture between schizophrenia and body mass index.
     Mol Psychiatry. 2023 May 18. doi: 10.1038/s41380-023-02104.
     PubMed     Abstract available
     
     
     
111. LEVITT JJ, Zhang F, Vangel M, Nestor PG, et al
     The organization of frontostriatal brain wiring in non-affective early psychosis compared with healthy subjects using a novel diffusion imaging fiber cluster analysis.
     Mol Psychiatry. 2023 May 12. doi: 10.1038/s41380-023-02031.
     PubMed     Abstract available
     
     
     
112. DWYER DB, Chand GB, Pigoni A, Khuntia A, et al
     Psychosis brain subtypes validated in first-episode cohorts and related to illness remission: results from the PHENOM consortium.
     Mol Psychiatry. 2023 May 5. doi: 10.1038/s41380-023-02069.
     PubMed     Abstract available
     
     
     
113. LICINIO J, Wong ML
     Psychosis and autism spectrum disorder: a special issue of Molecular Psychiatry.
     Mol Psychiatry. 2023;28:1830-1832.
     PubMed    
     
     
     April 2023
114. VAN DEN OORD EJCG, Xie LY, Zhao M, Campbell TL, et al
     Genes implicated by a methylome-wide schizophrenia study in neonatal blood show differential expression in adult brain samples.
     Mol Psychiatry. 2023 Apr 27. doi: 10.1038/s41380-023-02080.
     PubMed     Abstract available
     
     
     
115. CETIN-KARAYUMAK S, Lyall AE, Di Biase MA, Seitz-Holland J, et al
     Characterization of the extracellular free water signal in schizophrenia using multi-site diffusion MRI harmonization.
     Mol Psychiatry. 2023 Apr 24. doi: 10.1038/s41380-023-02068.
     PubMed     Abstract available
     
     
     
116. DE BARTOLOMEIS A, De Simone G, De Prisco M, Barone A, et al
     Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment.
     Mol Psychiatry. 2023 Apr 21. doi: 10.1038/s41380-023-02065.
     PubMed     Abstract available
     
     
     
117. ALAMEDA L, Liu Z, Sham PC, Aas M, et al
     Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis-findings from the EU-GEI study.
     Mol Psychiatry. 2023 Apr 17. doi: 10.1038/s41380-023-02044.
     PubMed     Abstract available
     
     
     
118. MAYELI A, LaGoy AD, Smagula SF, Wilson JD, et al
     Shared and distinct abnormalities in sleep-wake patterns and their relationship with the negative symptoms of Schizophrenia Spectrum Disorder patients.
     Mol Psychiatry. 2023 Apr 14. doi: 10.1038/s41380-023-02050.
     PubMed     Abstract available
     
     
     
119. HOWES OD, Onwordi EC
     The synaptic hypothesis of schizophrenia version III: a master mechanism.
     Mol Psychiatry. 2023 Apr 11. doi: 10.1038/s41380-023-02043.
     PubMed     Abstract available
     
     
     
120. MCWHINNEY SR, Brosch K, Calhoun VD, Crespo-Facorro B, et al
     Correction: Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals.
     Mol Psychiatry. 2023 Apr 4. doi: 10.1038/s41380-023-02055.
     PubMed    
     
     
     
121. ZWIR I, Arnedo J, Mesa A, Del Val C, et al
     Temperament & Character account for brain functional connectivity at rest: A diathesis-stress model of functional dysregulation in psychosis.
     Mol Psychiatry. 2023 Apr 4. doi: 10.1038/s41380-023-02039.
     PubMed     Abstract available
     
     
     
122. MOLLON J, Almasy L, Jacquemont S, Glahn DC, et al
     The contribution of copy number variants to psychiatric symptoms and cognitive ability.
     Mol Psychiatry. 2023;28:1480-1493.
     PubMed     Abstract available
     
     
     March 2023
123. GIANGRECO B, Dwir D, Klauser P, Jenni R, et al
     Characterization of early psychosis patients carrying a genetic vulnerability to redox dysregulation: a computational analysis of mechanism-based gene expression profile in fibroblasts.
     Mol Psychiatry. 2023 Mar 31. doi: 10.1038/s41380-023-02034.
     PubMed     Abstract available
     
     
     
124. RAMMOS A, Kirov G, Hubbard L, Walters JTR, et al
     Family-based analysis of the contribution of rare and common genetic variants to school performance in schizophrenia.
     Mol Psychiatry. 2023 Mar 13. doi: 10.1038/s41380-023-02013.
     PubMed     Abstract available
     
     
     
125. FOND G, Vidal M, Joseph M, Etchecopar-Etchart D, et al
     Self-stigma in schizophrenia: a systematic review and meta-analysis of 37 studies from 25 high- and low-to-middle income countries.
     Mol Psychiatry. 2023 Mar 8. doi: 10.1038/s41380-023-02003.
     PubMed     Abstract available
     
     
     
126. NAKAMURA T, Takata A
     The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research.
     Mol Psychiatry. 2023 Mar 6. doi: 10.1038/s41380-023-02005.
     PubMed     Abstract available
     
     
     
127. LIN JR, Zhao Y, Jabalameli MR, Nguyen N, et al
     Rare coding variants as risk modifiers of the 22q11.2 deletion implicate postnatal cortical development in syndromic schizophrenia.
     Mol Psychiatry. 2023 Mar 3. doi: 10.1038/s41380-023-02009.
     PubMed     Abstract available
     
     
     
128. LICINIO J, Wong ML
     Advances in Molecular Psychiatry - March 2023: mitochondrial function, stress, neuroinflammation - bipolar disorder, psychosis, and Alzheimer's disease.
     Mol Psychiatry. 2023;28:968-971.
     PubMed    
     
     
     
129. SAETHER LS, Ueland T, Haatveit B, Maglanoc LA, et al
     Inflammation and cognition in severe mental illness: patterns of covariation and subgroups.
     Mol Psychiatry. 2023;28:1284-1292.
     PubMed     Abstract available
     
     
     February 2023
130. MERRITT K, McCutcheon RA, Aleman A, Ashley S, et al
     Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis.
     Mol Psychiatry. 2023 Feb 17. doi: 10.1038/s41380-023-01991.
     PubMed     Abstract available
     
     
     
131. KOMATSU H, Onoguchi G, Jerotic S, Kanahara N, et al
     Correction: Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.
     Mol Psychiatry. 2023 Feb 9. doi: 10.1038/s41380-023-01983.
     PubMed    
     
     
     
132. LOTAN A, Luza S, Opazo CM, Ayton S, et al
     Perturbed iron biology in the prefrontal cortex of people with schizophrenia.
     Mol Psychiatry. 2023 Feb 7. doi: 10.1038/s41380-023-01979.
     PubMed     Abstract available
     
     
     
133. MCCUTCHEON RA, Keefe RSE, McGuire PK
     Correction: Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.
     Mol Psychiatry. 2023 Feb 2. doi: 10.1038/s41380-023-01984.
     PubMed    
     
     
     
134. WANG M, Barker PB, Cascella NG, Coughlin JM, et al
     Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study.
     Mol Psychiatry. 2023 Feb 2. doi: 10.1038/s41380-023-01969.
     PubMed     Abstract available
     
     
     January 2023
135. MCCUTCHEON RA, Keefe RSE, McGuire PK
     Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.
     Mol Psychiatry. 2023 Jan 23. doi: 10.1038/s41380-023-01949.
     PubMed     Abstract available
     
     
     
136. ENRICO P, Delvecchio G, Turtulici N, Aronica R, et al
     A machine learning approach on whole blood immunomarkers to identify an inflammation-associated psychosis onset subgroup.
     Mol Psychiatry. 2023 Jan 6. doi: 10.1038/s41380-022-01911.
     PubMed     Abstract available
     
     
     
137. FRISTON K
     Computational psychiatry: from synapses to sentience.
     Mol Psychiatry. 2023;28:256-268.
     PubMed     Abstract available
     
     
     December 2022
138. BARTH C, Kelly S, Nerland S, Jahanshad N, et al
     In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis.
     Mol Psychiatry. 2022 Dec 12. doi: 10.1038/s41380-022-01901.
     PubMed     Abstract available
     
     
     
139. CONSTANTINIDES C, Han LKM, Alloza C, Antonucci LA, et al
     Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium.
     Mol Psychiatry. 2022 Dec 9. doi: 10.1038/s41380-022-01897.
     PubMed     Abstract available
     
     
     November 2022
140. COLLINS MA, Ji JL, Chung Y, Lympus CA, et al
     Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk.
     Mol Psychiatry. 2022 Nov 25. doi: 10.1038/s41380-022-01870.
     PubMed     Abstract available
     
     
     
141. TAYLOR J, de Vries YA, van Loo HM, Kendler KS, et al
     Clinical characteristics indexing genetic differences in schizophrenia: a systematic review.
     Mol Psychiatry. 2022 Nov 18. doi: 10.1038/s41380-022-01850.
     PubMed     Abstract available
     
     
     
142. WEN J, Trost B, Engchuan W, Halvorsen M, et al
     Rare tandem repeat expansions associate with genes involved in synaptic and neuronal signaling functions in schizophrenia.
     Mol Psychiatry. 2022 Nov 16. pii: 10.1038/s41380-022-01857.
     PubMed     Abstract available
     
     
     
143. ENE HM, Karry R, Farfara D, Ben-Shachar D, et al
     Mitochondria play an essential role in the trajectory of adolescent neurodevelopment and behavior in adulthood: evidence from a schizophrenia rat model.
     Mol Psychiatry. 2022 Nov 15. pii: 10.1038/s41380-022-01865.
     PubMed     Abstract available
     
     
     
144. GOO BS, Mun DJ, Kim S, Nhung TTM, et al
     Schizophrenia-associated Mitotic Arrest Deficient-1 (MAD1) regulates the polarity of migrating neurons in the developing neocortex.
     Mol Psychiatry. 2022 Nov 10. pii: 10.1038/s41380-022-01856.
     PubMed     Abstract available
     
     
     
145. YEO IJ, Yun J, Son DJ, Han SB, et al
     Overexpression of transmembrane TNFalpha in brain endothelial cells induces schizophrenia-relevant behaviors.
     Mol Psychiatry. 2022 Nov 4. pii: 10.1038/s41380-022-01846.
     PubMed     Abstract available
     
     
     October 2022
146. WOLF G, Singh S, Blakolmer K, Lerer L, et al
     Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation.
     Mol Psychiatry. 2022 Oct 24. pii: 10.1038/s41380-022-01832.
     PubMed     Abstract available
     
     
     
147. TRINDADE P, Nascimento JM, Casas BS, Monteverde T, et al
     Induced pluripotent stem cell-derived astrocytes from patients with schizophrenia exhibit an inflammatory phenotype that affects vascularization.
     Mol Psychiatry. 2022 Oct 24. pii: 10.1038/s41380-022-01830.
     PubMed     Abstract available
     
     
     
148. MERIKANGAS AK, Almasy L
     Reply to "Comment on: What genes are differentially expressed in individuals with schizophrenia? A systematic review".
     Mol Psychiatry. 2022 Oct 12. pii: 10.1038/s41380-022-01821.
     PubMed    
     
     
     
149. BOYER L, Fond G, Pauly V, Orleans V, et al
     Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study.
     Mol Psychiatry. 2022 Oct 7. pii: 10.1038/s41380-022-01803.
     PubMed     Abstract available
     
     
     
150. PUVOGEL S, Alsema A, Kracht L, Webster MJ, et al
     Single-nucleus RNA sequencing of midbrain blood-brain barrier cells in schizophrenia reveals subtle transcriptional changes with overall preservation of cellular proportions and phenotypes.
     Mol Psychiatry. 2022 Oct 3. pii: 10.1038/s41380-022-01796.
     PubMed     Abstract available
     
     
     
151. FIKSINSKI AM, Hoftman GD, Vorstman JAS, Bearden CE, et al
     A genetics-first approach to understanding autism and schizophrenia spectrum disorders: the 22q11.2 deletion syndrome.
     Mol Psychiatry. 2022 Oct 3. pii: 10.1038/s41380-022-01783.
     PubMed     Abstract available
     
     
     September 2022
152. LENNOX B, Xiong W, Waters P, Coles A, et al
     The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis.
     Mol Psychiatry. 2022 Sep 21. pii: 10.1038/s41380-022-01784.
     PubMed     Abstract available
     
     
     
153. PISTIS G, Vazquez-Bourgon J, Fournier M, Jenni R, et al
     Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis.
     Mol Psychiatry. 2022 Sep 21. pii: 10.1038/s41380-022-01779.
     PubMed     Abstract available
     
     
     
154. YU G, Su Y, Guo C, Yi C, et al
     Pathological oligodendrocyte precursor cells revealed in human schizophrenic brains and trigger schizophrenia-like behaviors and synaptic defects in genetic animal model.
     Mol Psychiatry. 2022 Sep 21. pii: 10.1038/s41380-022-01777.
     PubMed     Abstract available
     
     
     
155. HOFFMAN GE, Jaffe AE, Gandal MJ, Collado-Torres L, et al
     Comment on: What genes are differentially expressed in individuals with schizophrenia? A systematic review.
     Mol Psychiatry. 2022 Sep 19. pii: 10.1038/s41380-022-01781.
     PubMed    
     
     
     
156. ALVER M, Lykoskoufis N, Ramisch A, Dermitzakis ET, et al
     Leveraging interindividual variability of regulatory activity for refining genetic regulation of gene expression in schizophrenia.
     Mol Psychiatry. 2022 Sep 16. pii: 10.1038/s41380-022-01768.
     PubMed     Abstract available
     
     
     
157. CHENG W, van der Meer D, Parker N, Hindley G, et al
     Shared genetic architecture between schizophrenia and subcortical brain volumes implicates early neurodevelopmental processes and brain development in childhood.
     Mol Psychiatry. 2022 Sep 13. pii: 10.1038/s41380-022-01751.
     PubMed     Abstract available
     
     
     August 2022
158. SOLMI M, Croatto G, Piva G, Rosson S, et al
     Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence.
     Mol Psychiatry. 2022 Aug 23. pii: 10.1038/s41380-022-01727.
     PubMed     Abstract available
     
     
     
159. SEITZ-HOLLAND J, Wojcik JD, Cetin-Karayumak S, Lyall AE, et al
     Cognitive deficits, clinical variables, and white matter microstructure in schizophrenia: a multisite harmonization study.
     Mol Psychiatry. 2022 Aug 18. pii: 10.1038/s41380-022-01731.
     PubMed     Abstract available
     
     
     
160. ZOGHBI AW, Lieberman JA, Girgis RR
     The neurobiology of duration of untreated psychosis: a comprehensive review.
     Mol Psychiatry. 2022 Aug 5. pii: 10.1038/s41380-022-01718.
     PubMed     Abstract available
     
     
     
161. SAPIENZA J, Bosia M, Spangaro M, Martini F, et al
     Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes.
     Mol Psychiatry. 2022 Aug 5. pii: 10.1038/s41380-022-01721.
     PubMed     Abstract available
     
     
     July 2022
162. MCWHINNEY SR, Brosch K, Calhoun VD, Crespo-Facorro B, et al
     Correction: Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals.
     Mol Psychiatry. 2022 Jul 20. pii: 10.1038/s41380-022-01696.
     PubMed    
     
     
     
163. BROSCH K, Stein F, Schmitt S, Pfarr JK, et al
     Reduced hippocampal gray matter volume is a common feature of patients with major depression, bipolar disorder, and schizophrenia spectrum disorders.
     Mol Psychiatry. 2022 Jul 15. pii: 10.1038/s41380-022-01687.
     PubMed     Abstract available
     
     
     
164. MASTROGIACOMO R, Trigilio G, Devroye C, Dautan D, et al
     Dysbindin-1A modulation of astrocytic dopamine and basal ganglia dependent behaviors relevant to schizophrenia.
     Mol Psychiatry. 2022 Jul 11. pii: 10.1038/s41380-022-01683.
     PubMed     Abstract available
     
     
     
165. ETCHECOPAR-ETCHART D, Mignon R, Boyer L, Fond G, et al
     Schizophrenia pregnancies should be given greater health priority in the global health agenda: results from a large-scale meta-analysis of 43,611 deliveries of women with schizophrenia and 40,948,272 controls.
     Mol Psychiatry. 2022 Jul 8. pii: 10.1038/s41380-022-01593.
     PubMed     Abstract available
     
     
     
166. CHIEN YL, Lin HY, Tung YH, Hwang TJ, et al
     Neurodevelopmental model of schizophrenia revisited: similarity in individual deviation and idiosyncrasy from the normative model of whole-brain white matter tracts and shared brain-cognition covariation with ADHD and ASD.
     Mol Psychiatry. 2022 Jul 6. pii: 10.1038/s41380-022-01636.
     PubMed     Abstract available
     
     
     June 2022
167. ALVER M, Mancini V, Lall K, Schneider M, et al
     Contribution of schizophrenia polygenic burden to longitudinal phenotypic variance in 22q11.2 deletion syndrome.
     Mol Psychiatry. 2022 Jun 29. pii: 10.1038/s41380-022-01674.
     PubMed     Abstract available
     
     
     
168. NI T, Zhu L, Wang S, Zhu W, et al
     Medial prefrontal cortex Notch1 signalling mediates methamphetamine-induced psychosis via Hes1-dependent suppression of GABAB1 receptor expression.
     Mol Psychiatry. 2022 Jun 22. pii: 10.1038/s41380-022-01662.
     PubMed     Abstract available
     
     
     
169. CASAS BS, Vitoria G, Prieto CP, Casas M, et al
     Schizophrenia-derived hiPSC brain microvascular endothelial-like cells show impairments in angiogenesis and blood-brain barrier function.
     Mol Psychiatry. 2022 Jun 15. pii: 10.1038/s41380-022-01653.
     PubMed     Abstract available
     
     
     
170. LIU D, Zinski A, Mishra A, Noh H, et al
     Impact of schizophrenia GWAS loci converge onto distinct pathways in cortical interneurons vs glutamatergic neurons during development.
     Mol Psychiatry. 2022 Jun 14. pii: 10.1038/s41380-022-01654.
     PubMed     Abstract available
     
     
     
171. MCWHINNEY SR, Brosch K, Calhoun VD, Crespo-Facorro B, et al
     Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals.
     Mol Psychiatry. 2022 Jun 14. pii: 10.1038/s41380-022-01616.
     PubMed     Abstract available
     
     
     
172. BUCK SA, Quincy Erickson-Oberg M, Logan RW, Freyberg Z, et al
     Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia.
     Mol Psychiatry. 2022 Jun 10. pii: 10.1038/s41380-022-01649.
     PubMed     Abstract available
     
     
     
173. AKINGBUWA WA, Hammerschlag AR, Bartels M, Nivard MG, et al
     Ultra-rare and common genetic variant analysis converge to implicate negative selection and neuronal processes in the aetiology of schizophrenia.
     Mol Psychiatry. 2022 Jun 3. pii: 10.1038/s41380-022-01621.
     PubMed     Abstract available
     
     
     
174. OLIVER D, Arribas M, Radua J, Salazar de Pablo G, et al
     Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis.
     Mol Psychiatry. 2022 Jun 3. pii: 10.1038/s41380-022-01611.
     PubMed     Abstract available
     
     
     
175. HYDE J, Carr H, Kelley N, Seneviratne R, et al
     Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials.
     Mol Psychiatry. 2022;27:2709-2719.
     PubMed     Abstract available
     
     
     May 2022
176. KOMATSU H, Onoguchi G, Jerotic S, Kanahara N, et al
     Correction: Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.
     Mol Psychiatry. 2022 May 27. pii: 10.1038/s41380-022-01620.
     PubMed    
     
     
     
177. MATLIK K, Garton DR, Montano-Rodriguez AR, Olfat S, et al
     Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia.
     Mol Psychiatry. 2022 May 26. pii: 10.1038/s41380-022-01554.
     PubMed     Abstract available
     
     
     
178. MOJARAD BA, Engchuan W, Trost B, Backstrom I, et al
     Genome-wide tandem repeat expansions contribute to schizophrenia risk.
     Mol Psychiatry. 2022 May 12. pii: 10.1038/s41380-022-01575.
     PubMed     Abstract available
     
     
     
179. FASS DM, Lewis MC, Ahmad R, Szucs MJ, et al
     Brain-specific deletion of GIT1 impairs cognition and alters phosphorylation of synaptic protein networks implicated in schizophrenia susceptibility.
     Mol Psychiatry. 2022 May 3. pii: 10.1038/s41380-022-01557.
     PubMed     Abstract available
     
     
     
180. SAARINEN A, Lyytikainen LP, Hietala J, Dobewall H, et al
     Magical thinking in individuals with high polygenic risk for schizophrenia but no non-affective psychoses-a general population study.
     Mol Psychiatry. 2022 May 3. pii: 10.1038/s41380-022-01581.
     PubMed     Abstract available
     
     
     
181. KOMATSU H, Onoguchi G, Jerotic S, Kanahara N, et al
     Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.
     Mol Psychiatry. 2022 May 2. pii: 10.1038/s41380-022-01591.
     PubMed     Abstract available
     
     
     April 2022
182. CUENOD M, Steullet P, Cabungcal JH, Dwir D, et al
     Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia; Response to "Adaptive changes to oxidative stress in schizophrenia by Lena Palaniyappan".
     Mol Psychiatry. 2022 Apr 28. pii: 10.1038/s41380-022-01553.
     PubMed    
     
     
     
183. WADA M, Noda Y, Iwata Y, Tsugawa S, et al
     Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.
     Mol Psychiatry. 2022 Apr 20. pii: 10.1038/s41380-022-01572.
     PubMed     Abstract available
     
     
     
184. ABU-AKEL A, Wood SJ, Upthegrove R, Chisholm K, et al
     Psychosocial functioning in the balance between autism and psychosis: evidence from three populations.
     Mol Psychiatry. 2022 Apr 14. pii: 10.1038/s41380-022-01543.
     PubMed     Abstract available
     
     
     
185. ABRAM SV, Roach BJ, Fryer SL, Calhoun VD, et al
     Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia.
     Mol Psychiatry. 2022 Apr 14. pii: 10.1038/s41380-022-01502.
     PubMed     Abstract available
     
     
     
186. ALMULLA AF, Vasupanrajit A, Tunvirachaisakul C, Al-Hakeim HK, et al
     The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.
     Mol Psychiatry. 2022 Apr 14. pii: 10.1038/s41380-022-01552.
     PubMed     Abstract available
     
     
     
187. PALANIYAPPAN L
     Adaptive changes to oxidative stress in schizophrenia.
     Mol Psychiatry. 2022 Apr 8. pii: 10.1038/s41380-022-01550.
     PubMed    
     
     
     
188. AYORA M, Fraguas D, Abregu-Crespo R, Recio S, et al
     Leukocyte telomere length in patients with schizophrenia and related disorders: a meta-analysis of case-control studies.
     Mol Psychiatry. 2022 Apr 7. pii: 10.1038/s41380-022-01541.
     PubMed     Abstract available
     
     
     
189. SONG J, Yao S, Kowalec K, Lu Y, et al
     The impact of educational attainment, intelligence and intellectual disability on schizophrenia: a Swedish population-based register and genetic study.
     Mol Psychiatry. 2022 Apr 5. pii: 10.1038/s41380-022-01500.
     PubMed     Abstract available
     
     
     
190. BELLON A, Feuillet V, Cortez-Resendiz A, Mouaffak F, et al
     Dopamine-induced pruning in monocyte-derived-neuronal-like cells (MDNCs) from patients with schizophrenia.
     Mol Psychiatry. 2022 Apr 1. pii: 10.1038/s41380-022-01514.
     PubMed     Abstract available
     
     
     
191. REN D, Wei X, Lin L, Yuan F, et al
     A novel heterozygous missense variant of the ARID4A gene identified in Han Chinese families with schizophrenia-diagnosed siblings that interferes with DNA-binding activity.
     Mol Psychiatry. 2022 Apr 1. pii: 10.1038/s41380-022-01530.
     PubMed     Abstract available
     
     
     
192. PERZEL MANDELL KA, Eagles NJ, Deep-Soboslay A, Tao R, et al
     Molecular phenotypes associated with antipsychotic drugs in the human caudate nucleus.
     Mol Psychiatry. 2022;27:2061-2067.
     PubMed     Abstract available
     
     
     March 2022
193. HENKEL ND, Wu X, O'Donovan SM, Devine EA, et al
     Schizophrenia: a disorder of broken brain bioenergetics.
     Mol Psychiatry. 2022 Mar 9. pii: 10.1038/s41380-022-01494.
     PubMed     Abstract available
     
     
     
194. MEALER RG, Williams SE, Noel M, Yang B, et al
     The schizophrenia-associated variant in SLC39A8 alters protein glycosylation in the mouse brain.
     Mol Psychiatry. 2022 Mar 8. pii: 10.1038/s41380-022-01490.
     PubMed     Abstract available
     
     
     February 2022
195. MCGUINNESS AJ, Davis JA, Dawson SL, Loughman A, et al
     A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia.
     Mol Psychiatry. 2022 Feb 22. pii: 10.1038/s41380-022-01456.
     PubMed     Abstract available
     
     
     
196. HWANG I, Kim BS, Ko HR, Cho S, et al
     Cerebellar dysfunction and schizophrenia-like behavior in Ebp1-deficient mice.
     Mol Psychiatry. 2022 Feb 15. pii: 10.1038/s41380-022-01458.
     PubMed     Abstract available
     
     
     
197. DI BIASE MA, Geaghan MP, Reay WR, Seidlitz J, et al
     Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia.
     Mol Psychiatry. 2022 Feb 10. pii: 10.1038/s41380-022-01460.
     PubMed     Abstract available
     
     
     
198. OLISLAGERS M, Rademaker K, Adan RAH, Lin BD, et al
     Comprehensive analyses of RNA-seq and genome-wide data point to enrichment of neuronal cell type subsets in neuropsychiatric disorders.
     Mol Psychiatry. 2022;27:947-955.
     PubMed     Abstract available
     
     
     
199. KIRSCHNER M, Hodzic-Santor B, Antoniades M, Nenadic I, et al
     Cortical and subcortical neuroanatomical signatures of schizotypy in 3004 individuals assessed in a worldwide ENIGMA study.
     Mol Psychiatry. 2022;27:1167-1176.
     PubMed     Abstract available
     
     
     January 2022
200. MERIKANGAS AK, Shelly M, Knighton A, Kotler N, et al
     What genes are differentially expressed in individuals with schizophrenia? A systematic review.
     Mol Psychiatry. 2022 Jan 28. pii: 10.1038/s41380-021-01420.
     PubMed     Abstract available
     
     
     
201. EL KHOUEIRY C, Cabungcal JH, Rovo Z, Fournier M, et al
     Developmental oxidative stress leads to T-type Ca(2+) channel hypofunction in thalamic reticular nucleus of mouse models pertinent to schizophrenia.
     Mol Psychiatry. 2022 Jan 25. pii: 10.1038/s41380-021-01425.
     PubMed     Abstract available
     
     
     
202. LI W, Lv L, Luo XJ
     In vivo study sheds new light on the dendritic spine pathology hypothesis of schizophrenia.
     Mol Psychiatry. 2022 Jan 25. pii: 10.1038/s41380-022-01449.
     PubMed    
     
     
     
203. SIMPSON EH, Gallo EF, Balsam PD, Javitch JA, et al
     How changes in dopamine D2 receptor levels alter striatal circuit function and motivation.
     Mol Psychiatry. 2022;27:436-444.
     PubMed     Abstract available
     
     
     
204. NAIR PC, Miners JO, McKinnon RA, Langmead CJ, et al
     Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs.
     Mol Psychiatry. 2022;27:88-94.
     PubMed     Abstract available
     
     
     December 2021
205. ERADY C, Amin K, Onilogbo TOAE, Tomasik J, et al
     Novel open reading frames in human accelerated regions and transposable elements reveal new leads to understand schizophrenia and bipolar disorder.
     Mol Psychiatry. 2021 Dec 23. pii: 10.1038/s41380-021-01405.
     PubMed     Abstract available
     
     
     
206. HASSAN L, Peek N, Lovell K, Carvalho AF, et al
     Disparities in COVID-19 infection, hospitalisation and death in people with schizophrenia, bipolar disorder, and major depressive disorder: a cohort study of the UK Biobank.
     Mol Psychiatry. 2021 Dec 7. pii: 10.1038/s41380-021-01344.
     PubMed     Abstract available
     
     
     
207. BAGAUTDINOVA J, Zoller D, Schaer M, Padula MC, et al
     Altered cortical thickness development in 22q11.2 deletion syndrome and association with psychotic symptoms.
     Mol Psychiatry. 2021;26:7671-7678.
     PubMed     Abstract available
     
     
     November 2021
208. ALKELAI A, Greenbaum L, Docherty AR, Shabalin AA, et al
     The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders.
     Mol Psychiatry. 2021 Nov 19. pii: 10.1038/s41380-021-01383.
     PubMed     Abstract available
     
     
     
209. ZHANG R, Sjolander A, Ploner A, Lu D, et al
     Novel disease associations with schizophrenia genetic risk revealed in ~400,000 UK Biobank participants.
     Mol Psychiatry. 2021 Nov 19. pii: 10.1038/s41380-021-01387.
     PubMed     Abstract available
     
     
     
210. NOTARAS M, Lodhi A, Dundar F, Collier P, et al
     Schizophrenia is defined by cell-specific neuropathology and multiple neurodevelopmental mechanisms in patient-derived cerebral organoids.
     Mol Psychiatry. 2021 Nov 17. pii: 10.1038/s41380-021-01316.
     PubMed     Abstract available
     
     
     
211. EISENBERG DP, Kohn PD, Hegarty CE, Smith NR, et al
     Clinical correlation but no elevation of striatal dopamine synthesis capacity in two independent cohorts of medication-free individuals with schizophrenia.
     Mol Psychiatry. 2021 Nov 17. pii: 10.1038/s41380-021-01337.
     PubMed     Abstract available
     
     
     
212. PLAVEN-SIGRAY P, Ikonen Victorsson P, Santillo A, Matheson GJ, et al
     Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis.
     Mol Psychiatry. 2021 Nov 10. pii: 10.1038/s41380-021-01349.
     PubMed     Abstract available
     
     
     
213. CUENOD M, Steullet P, Cabungcal JH, Dwir D, et al
     Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia.
     Mol Psychiatry. 2021 Nov 10. pii: 10.1038/s41380-021-01374.
     PubMed     Abstract available
     
     
     
214. ZHOU X
     Over-representation of potential SP4 target genes within schizophrenia-risk genes.
     Mol Psychiatry. 2021 Nov 8. pii: 10.1038/s41380-021-01376.
     PubMed     Abstract available
     
     
     
215. SELLGREN CM, Imbeault S, Larsson MK, Oliveros A, et al
     Correction: GRK3 deficiency elicits brain immune activation and psychosis.
     Mol Psychiatry. 2021 Nov 8. pii: 10.1038/s41380-021-01371.
     PubMed    
     
     
     
216. CAMPEAU A, Mills RH, Stevens T, Rossitto LA, et al
     Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia.
     Mol Psychiatry. 2021 Nov 5. pii: 10.1038/s41380-021-01339.
     PubMed     Abstract available
     
     
     
217. GAO Y, Fan Y, Yang Z, Ma Q, et al
     Systems biological assessment of altered cytokine responses to bacteria and fungi reveals impaired immune functionality in schizophrenia.
     Mol Psychiatry. 2021 Nov 2. pii: 10.1038/s41380-021-01362.
     PubMed     Abstract available
     
     
     
218. LI Q, Wang Z, Zong L, Ye L, et al
     Allele-specific DNA methylation maps in monozygotic twins discordant for psychiatric disorders reveal that disease-associated switching at the EIPR1 regulatory loci modulates neural function.
     Mol Psychiatry. 2021;26:6630-6642.
     PubMed     Abstract available
     
     
     October 2021
219. CHAN SY, Brady RO, Lewandowski KE, Higgins A, et al
     Dynamic and progressive changes in thalamic functional connectivity over the first five years of psychosis.
     Mol Psychiatry. 2021 Oct 25. pii: 10.1038/s41380-021-01319.
     PubMed     Abstract available
     
     
     
220. KHADIMALLAH I, Jenni R, Cabungcal JH, Cleusix M, et al
     Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia.
     Mol Psychiatry. 2021 Oct 22. pii: 10.1038/s41380-021-01313.
     PubMed     Abstract available
     
     
     
221. WOLF DH, Zheng D, Kohler C, Turetsky BI, et al
     Effect of mGluR2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia.
     Mol Psychiatry. 2021 Oct 20. pii: 10.1038/s41380-021-01320.
     PubMed     Abstract available
     
     
     
222. YANG K, Longo L, Narita Z, Cascella N, et al
     A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance.
     Mol Psychiatry. 2021 Oct 12. pii: 10.1038/s41380-021-01331.
     PubMed     Abstract available
     
     
     September 2021
223. LUO C, Pi X, Hu N, Wang X, et al
     Subtypes of schizophrenia identified by multi-omic measures associated with dysregulated immune function.
     Mol Psychiatry. 2021 Sep 29. pii: 10.1038/s41380-021-01308.
     PubMed     Abstract available
     
     
     
224. NAKAHARA T, Tsugawa S, Noda Y, Ueno F, et al
     Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies.
     Mol Psychiatry. 2021 Sep 28. pii: 10.1038/s41380-021-01297.
     PubMed     Abstract available
     
     
     
225. SAARENTAUS EC, Havulinna AS, Mars N, Ahola-Olli A, et al
     Polygenic burden has broader impact on health, cognition, and socioeconomic outcomes than most rare and high-risk copy number variants.
     Mol Psychiatry. 2021;26:4884-4895.
     PubMed     Abstract available
     
     
     
226. JIA X, Goes FS, Locke AE, Palmer D, et al
     Investigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder.
     Mol Psychiatry. 2021;26:5239-5250.
     PubMed     Abstract available
     
     
     August 2021
227. STAUFFER EM, Bethlehem RAI, Warrier V, Murray GK, et al
     Grey and white matter microstructure is associated with polygenic risk for schizophrenia.
     Mol Psychiatry. 2021 Aug 30. pii: 10.1038/s41380-021-01260.
     PubMed     Abstract available
     
     
     
228. LI Y, Li S, Liu J, Huo Y, et al
     The schizophrenia susceptibility gene NAGA regulates dendritic spine density: further evidence for the dendritic spine pathology of schizophrenia.
     Mol Psychiatry. 2021 Aug 10. pii: 10.1038/s41380-021-01261.
     PubMed    
     
     
     
229. RAUBER S, Heming M, Repple J, Ruland T, et al
     Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses.
     Mol Psychiatry. 2021 Aug 6. pii: 10.1038/s41380-021-01244.
     PubMed     Abstract available
     
     
     
230. TAKAYANAGI Y, Ishizuka K, Laursen TM, Yukitake H, et al
     From population to neuron: exploring common mediators for metabolic problems and mental illnesses.
     Mol Psychiatry. 2021;26:3931-3942.
     PubMed     Abstract available
     
     
     
231. NI C, Jiang W, Wang Z, Wang Z, et al
     LncRNA-AC006129.1 reactivates a SOCS3-mediated anti-inflammatory response through DNA methylation-mediated CIC downregulation in schizophrenia.
     Mol Psychiatry. 2021;26:4511-4528.
     PubMed     Abstract available
     
     
     
232. CLEYNEN I, Engchuan W, Hestand MS, Heung T, et al
     Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion.
     Mol Psychiatry. 2021;26:4496-4510.
     PubMed     Abstract available
     
     
     
233. GOBSHTIS N, Tfilin M, Fraifeld VE, Turgeman G, et al
     Transplantation of mesenchymal stem cells causes long-term alleviation of schizophrenia-like behaviour coupled with increased neurogenesis.
     Mol Psychiatry. 2021;26:4448-4463.
     PubMed     Abstract available
     
     
     
234. GREENING DW, Notaras M, Chen M, Xu R, et al
     Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome.
     Mol Psychiatry. 2021;26:4431-4447.
     PubMed     Abstract available
     
     
     
235. HARRISON PJ, Hall N, Mould A, Al-Juffali N, et al
     Cellular calcium in bipolar disorder: systematic review and meta-analysis.
     Mol Psychiatry. 2021;26:4106-4116.
     PubMed     Abstract available
     
     
     
236. BORGAN F, O'Daly O, Veronese M, Reis Marques T, et al
     The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study.
     Mol Psychiatry. 2021;26:4464-4474.
     PubMed     Abstract available
     
     
     
237. KOWALEC K, Lu Y, Sariaslan A, Song J, et al
     Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study.
     Mol Psychiatry. 2021;26:4487-4495.
     PubMed     Abstract available
     
     
     July 2021
238. LIU Z, Palaniyappan L, Wu X, Zhang K, et al
     Resolving heterogeneity in schizophrenia through a novel systems approach to brain structure: individualized structural covariance network analysis.
     Mol Psychiatry. 2021 Jul 28. pii: 10.1038/s41380-021-01229.
     PubMed     Abstract available
     
     
     
239. MURPHY CE, Weickert CS
     A new suspect in the unsolved case of neuroinflammation in schizophrenia.
     Mol Psychiatry. 2021 Jul 20. pii: 10.1038/s41380-021-01225.
     PubMed    
     
     
     
240. WU X, Shukla R, Alganem K, Zhang X, et al
     Transcriptional profile of pyramidal neurons in chronic schizophrenia reveals lamina-specific dysfunction of neuronal immunity.
     Mol Psychiatry. 2021 Jul 16. pii: 10.1038/s41380-021-01205.
     PubMed     Abstract available
     
     
     
241. HEURICH M, Focking M, Mongan D, Cagney G, et al
     Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis.
     Mol Psychiatry. 2021 Jul 5. pii: 10.1038/s41380-021-01197.
     PubMed     Abstract available
     
     
     
242. SHA Z, Schijven D, Francks C
     Patterns of brain asymmetry associated with polygenic risks for autism and schizophrenia implicate language and executive functions but not brain masculinization.
     Mol Psychiatry. 2021 Jul 1. pii: 10.1038/s41380-021-01204.
     PubMed     Abstract available
     
     
     
243. STEIXNER-KUMAR AA, Daguano Gastaldi V, Seidel J, Rosenberger A, et al
     Preadult polytoxicomania-strong environmental underpinnings and first genetic hints.
     Mol Psychiatry. 2021;26:3211-3222.
     PubMed     Abstract available
     
     
     
244. CLIFTON NE, Rees E, Holmans PA, Pardinas AF, et al
     Genetic association of FMRP targets with psychiatric disorders.
     Mol Psychiatry. 2021;26:2977-2990.
     PubMed     Abstract available
     
     
     June 2021
245. ZHU X, Cabungcal JH, Cuenod M, Uliana DL, et al
     Thalamic reticular nucleus impairments and abnormal prefrontal control of dopamine system in a developmental model of schizophrenia: prevention by N-acetylcysteine.
     Mol Psychiatry. 2021 Jun 30. pii: 10.1038/s41380-021-01198.
     PubMed     Abstract available
     
     
     
246. GUAN F, Ni T, Zhu W, Williams LK, et al
     Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction.
     Mol Psychiatry. 2021 Jun 30. pii: 10.1038/s41380-021-01201.
     PubMed     Abstract available
     
     
     
247. GAO WJ, Yang SS, Mack NR, Chamberlin LA, et al
     Aberrant maturation and connectivity of prefrontal cortex in schizophrenia-contribution of NMDA receptor development and hypofunction.
     Mol Psychiatry. 2021 Jun 23. pii: 10.1038/s41380-021-01196.
     PubMed     Abstract available
     
     
     
248. ROGDAKI M, Devroye C, Ciampoli M, Veronese M, et al
     Correction: Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.
     Mol Psychiatry. 2021 Jun 22. pii: 10.1038/s41380-021-01192.
     PubMed    
     
     
     
249. RADHAKRISHNAN R, Skosnik PD, Ranganathan M, Naganawa M, et al
     In vivo evidence of lower synaptic vesicle density in schizophrenia.
     Mol Psychiatry. 2021 Jun 16. pii: 10.1038/s41380-021-01184.
     PubMed     Abstract available
     
     
     
250. DEMICHELE-SWEET MAA, Klei L, Creese B, Harwood JC, et al
     Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease.
     Mol Psychiatry. 2021 Jun 10. pii: 10.1038/s41380-021-01152.
     PubMed     Abstract available
     
     
     
251. TIGARET CM, Lin TE, Morrell ER, Sykes L, et al
     Neurotrophin receptor activation rescues cognitive and synaptic abnormalities caused by hemizygosity of the psychiatric risk gene Cacna1c.
     Mol Psychiatry. 2021;26:1748-1760.
     PubMed     Abstract available
     
     
     
252. BYRNE EM, Zhu Z, Qi T, Skene NG, et al
     Conditional GWAS analysis to identify disorder-specific SNPs for psychiatric disorders.
     Mol Psychiatry. 2021;26:2070-2081.
     PubMed     Abstract available
     
     
     
253. PEREZ JM, Berto S, Gleason K, Ghose S, et al
     Hippocampal subfield transcriptome analysis in schizophrenia psychosis.
     Mol Psychiatry. 2021;26:2577-2589.
     PubMed     Abstract available
     
     
     
254. CAO H, Zhou H, Cannon TD
     Functional connectome-wide associations of schizophrenia polygenic risk.
     Mol Psychiatry. 2021;26:2553-2561.
     PubMed     Abstract available
     
     
     
255. MA L, Shcherbina A, Chetty S
     Variations and expression features of CYP2D6 contribute to schizophrenia risk.
     Mol Psychiatry. 2021;26:2605-2615.
     PubMed     Abstract available
     
     
     May 2021
256. WEISSLEDER C, North HF, Bitar M, Fullerton JM, et al
     Reduced adult neurogenesis is associated with increased macrophages in the subependymal zone in schizophrenia.
     Mol Psychiatry. 2021 May 31. pii: 10.1038/s41380-021-01149.
     PubMed     Abstract available
     
     
     
257. DI BIASE MA, Cetin-Karayumak S, Lyall AE, Zalesky A, et al
     White matter changes in psychosis risk relate to development and are not impacted by the transition to psychosis.
     Mol Psychiatry. 2021 May 24. pii: 10.1038/s41380-021-01128.
     PubMed     Abstract available
     
     
     
258. CHADHA R, Alganem K, Mccullumsmith RE, Meador-Woodruff JH, et al
     mTOR kinase activity disrupts a phosphorylation signaling network in schizophrenia brain.
     Mol Psychiatry. 2021 May 14. pii: 10.1038/s41380-021-01135.
     PubMed     Abstract available
     
     
     
259. KARIMI B, Silwal P, Booth S, Padmanabhan N, et al
     Schizophrenia-associated LRRTM1 regulates cognitive behavior through controlling synaptic function in the mediodorsal thalamus.
     Mol Psychiatry. 2021 May 12. pii: 10.1038/s41380-021-01146.
     PubMed     Abstract available
     
     
     
260. ROGDAKI M, Devroye C, Ciampoli M, Veronese M, et al
     Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.
     Mol Psychiatry. 2021 May 12. pii: 10.1038/s41380-021-01108.
     PubMed     Abstract available
     
     
     
261. SELLGREN CM, Imbeault S, Larsson MK, Oliveros A, et al
     GRK3 deficiency elicits brain immune activation and psychosis.
     Mol Psychiatry. 2021 May 12. pii: 10.1038/s41380-021-01106.
     PubMed     Abstract available
     
     
     April 2021
262. LI Y, Ma C, Li W, Yang Y, et al
     A missense variant in NDUFA6 confers schizophrenia risk by affecting YY1 binding and NAGA expression.
     Mol Psychiatry. 2021 Apr 30. pii: 10.1038/s41380-021-01125.
     PubMed     Abstract available
     
     
     
263. SHEN M, Guo Y, Dong Q, Gao Y, et al
     FXR1 regulation of parvalbumin interneurons in the prefrontal cortex is critical for schizophrenia-like behaviors.
     Mol Psychiatry. 2021 Apr 16. pii: 10.1038/s41380-021-01096.
     PubMed     Abstract available
     
     
     
264. DRUART M, Nosten-Bertrand M, Poll S, Crux S, et al
     Elevated expression of complement C4 in the mouse prefrontal cortex causes schizophrenia-associated phenotypes.
     Mol Psychiatry. 2021 Apr 9. pii: 10.1038/s41380-021-01081.
     PubMed     Abstract available
     
     
     
265. ANDLAUER TFM, Guzman-Parra J, Streit F, Strohmaier J, et al
     Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders.
     Mol Psychiatry. 2021;26:1286-1298.
     PubMed     Abstract available
     
     
     
266. LEGGIO GM, Torrisi SA, Mastrogiacomo R, Mauro D, et al
     The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans.
     Mol Psychiatry. 2021;26:1272-1285.
     PubMed     Abstract available
     
     
     March 2021
267. SINHA V, Ukkola-Vuoti L, Ortega-Alonso A, Torniainen-Holm M, et al
     Variants in regulatory elements of PDE4D associate with major mental illness in the Finnish population.
     Mol Psychiatry. 2021;26:816-824.
     PubMed     Abstract available
     
     
     February 2021
268. RATHJE M, Waxman H, Benoit M, Tammineni P, et al
     Genetic variants in the bipolar disorder risk locus SYNE1 that affect CPG2 expression and protein function.
     Mol Psychiatry. 2021;26:508-523.
     PubMed     Abstract available
     
     
     January 2021
269. NORTHOFF G, Hirjak D, Wolf RC, Magioncalda P, et al
     All roads lead to the motor cortex: psychomotor mechanisms and their biochemical modulation in psychiatric disorders.
     Mol Psychiatry. 2021;26:92-102.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.